Overall, the antitumor activity was promising in EGFRm NSCLC patients receiving anti-CD73/anti-PD-L1 therapy, whereas the effectiveness in CRC and PDAC is yet to be verified (34). Here, CD274 is linked to colorectal carcinoma.